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This paper describes a microfluidic device for dry preservation of biological specimens at room temperature that
incorporates chemical stabilization matrices. Long-term stabilization of samples is crucial for remote medical analy-
sis, biosurveillance, and archiving, but the current paradigm for transporting remotely obtained samples relies on
the costly “cold chain” to preserve analytes within biospecimens. We propose an alternative approach that involves
the use of microfluidics to preserve samples in the dry state with stabilization matrices, developed by others, that
are based on self-preservation chemistries found in nature. We describe a SlipChip-based device that allows mini-
mally trained users to preserve samples with the three simple steps of placing a sample at an inlet, closing a lid,
and slipping one layer of the device. The device fills automatically, and a pre-loaded desiccant dries the samples.
Later, specimens can be rehydrated and recovered for analysis in a laboratory. This device is portable, compact,
and self-contained, so it can be transported and operated by untrained users even in limited-resource settings. Fea-
tures such as dead-end and sequential filling, combined with a “pumping lid” mechanism, enable precise quantifi-
cation of the original sample’s volume while avoiding overfilling. In addition, we demonstrated that the device can
be integrated with a plasma filtration module, and we validated device operations and capabilities by testing the
stability of purified RNA solutions. These features and the modularity of this platform (which facilitates integration
and simplifies operation) would be applicable to other microfluidic devices beyond this application. We envision
that as the field of stabilization matrices develops, microfluidic devices will be useful for cost-effectively facilitating
remote analysis and biosurveillance while also opening new opportunities for diagnostics, drug development, and
other medical fields.Introduction
Here, we describe a microfluidic device for dry preservation
of biological specimens at room temperature. Stabilization of
blood, saliva, urine, or other biospecimens is important for
bridging on-site analysis in limited-resource settings—where
electricity and equipment are non-existent or scarce—with
central laboratories and biological archives. For example,
while point-of-care assays allow testing of some biomarkers,
these assays usually require complementary follow-up tests
that are not available in a portable format. In the case of
monitoring antiretroviral therapies for HIV and HCV treat-
ments, for instance, while the initial diagnosis can be per-
formed at the point of care, the follow-up assessments to
determine the correct treatment are required.1,2 These tests,
which may involve sequencing and viral load measurements,
currently need to be performed in a centralized laboratory. Inaddition to facilitating follow-up analysis, stabilization is cru-
cial for the biosurveillance of emerging infectious diseases,
since analytes must be stabilized as samples travel from
remote locations to central laboratories.3 Stabilization of ana-
lytes also aids biobanking and archiving, as biobanks that
store large quantities of clinical samples for future study
must preserve specimens for extended periods of time.4–6
Generally, analytes are kept stable using the “cold chain,”
in which samples are transported in dry ice and stored in
freezers. The cost and complexity of low-temperature stabili-
zation limit the applications of biosurveillance and follow-up
tests.7 Furthermore, freezers that house specimens require
electricity, putting samples at risk of destruction in the event
of power failure.8,9 And while the cold chain addresses the
question of storing specimens, it does not account for other
needs of remote analysis. For instance, many biospecimens
must be specially prepared at the moment of collection in
order to be studied further. In the case of blood biomarkers,
analysis is typically performed on serum or cell-free plasma,10
which must be obtained by trained personnel using specific
equipment, such as a centrifuge.
Dried blood spots (DBS) have been used as one alternative
to the cold chain. This method involves drying whole blood2013, 13, 4331–4342 | 4331
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View Article Onlineon filter paper to stabilize the sample. Recovery is performed
by removing a portion of the blood spot with a hole punch
and using a combination of solvents and buffers to elute the
sample from the resulting punched-out disc. This method
does not require sample preparation or specialized equip-
ment at the moment of sample collection, and has been used
for large-scale neonatal screening and biosurveillance.11 How-
ever, the use of DBS for quantitative analyses presents some
challenges and limitations, as results are dependent on the
hematocrit and on where the punch is taken on the paper,12
and samples can be contaminated by open-air exposure or
cross-contaminated by the biopsy punch tool. Furthermore,
long drying times and external conditions such as humidity
may compromise the stability of analytes: for this reason,
most protocols require freezing of DBS for long-term stor-
age.13,14 Finally, serum or cell-free plasma, rather than whole
blood, are often the matrices of choice for clinical tests; to
implement DBS, specific elution procedures need to be opti-
mized for purifying analytes and avoiding interference from
residual components in blood. Although dried plasma spots
can address some limitations of DBS, they require trained
personnel to perform plasma separation.
Chemical stabilization matrices offer an alternative to the
cold chain and DBS, but until now, they have not been com-
patible with devices for resource-limited settings. A number of
matrices have been developed, many of which rely on natural
chemistries used by living organisms for self-preservation.15
Several commercially available stabilization matrices
(Biomatrica, GenTegra, etc.) preserve samples in the dry
state. Drying inhibits analyte degradation linked to enzy-
matic activity and slows down reactions that are activated by
light or heat.16,17 These matrices do not necessarily solve the
problem of sample preparation, but they do allow long-term
storage of DNA and RNA at room temperature. Current pro-
tocols for using these stabilization matrices are suitable for
laboratory use, but drying the samples typically requires
vacuum conditions or external devices (e.g., lyophilizer,
pumps, vacuum concentrators) to control humidity, as well
as experienced personnel to process the sample.18,19 Portable
devices have been proposed,20 but these usually involve elec-
tricity and long drying times (from a few hours to overnight).
Alternatively, drying can be done without the use of external
equipment by exposing the sample to the environment, but
airborne contaminants may come into contact with the sam-
ple and drying times are dependent on external conditions
such as humidity. Moreover, leaving the tubes or titer plates
open during drying may lead to cross-contamination between
different samples: to solve this problem, one needs to use
porous seals (which increase drying times) or a dedicated
device20 for preventing aerosol-driven cross-contamination.
An approach that offers reliable preservation, avoids con-
tamination, allows quantitative measurements, is compatible
with sample preparation, and can be executed by minimally
trained users is needed. Herein, we describe a device that
meets these requirements and can be used with commercially
available sample preservation matrices.4332 | Lab Chip, 2013, 13, 4331–4342Experimental
Structure of devices
The device was based on SlipChip technology.21 Devices
described in this paper comprised three different subassem-
blies (Part 1, Part 2, Part 3, hereafter referred to as P1, P2,
P3), made of a combination of poly(methyl methacrylate) and
polyethylene terephthalate layers. A full description of the
layer configuration is shown in the ESI† (Fig. S1 and S2). The
central portion (P2) included a Polypropylene Membrane
Filter, 0.45 pore size (Sterlitech Corp., Kent, WA, USA). For
plasma experiments, the top part (P1) also included a Vivid
Plasma Separation Membrane (Grade GR) (Pall Corp., Port
Washington, NY, USA).
Production of devices
The devices described in this paper are prototypes, but they
were designed in consultation with manufacturing partners
to be compatible with mass production (see Fig. S3 in the
ESI† for different prototypes). At the device development
stage, we used laser cutting since it is suitable for prototyping
and allows great flexibility in design and materials selection.
This technique allowed us to produce batches on the
100-device scale. However, since laser cutting requires multi-
ple device layers, we also designed the device so that it would
be easily adaptable to large-scale manufacturing techniques,
such as injection molding. We make the assumption that
injection molding would be an inexpensive process to mass-
produce these devices, but full economic analysis of the
manufacturing process is outside of the scope of this manu-
script. The geometry of each layer was designed using CAD
software, and the pattern was used to produce through-holes
or channels in a polymeric sheet of desired thickness. This
design was used by ALine Inc. (Rancho Dominguez, CA, USA)
to fabricate devices using laser cutting and lamination for
rapid prototyping. Layers were then aligned and bonded by
lamination, using pressure sensitive adhesive or thermal
adhesives. Clamping systems were custom-designed and pro-
duced either by using 3D printing (by Symbient Product
Development, Vista, CA, USA) or by laser cutting (by ALine or
at the Jim Hall Design and Prototyping Lab at the California
Institute of Technology). Pumping lids were produced using
laser cutting of poly(methyl methacrylate) in the Jim Hall
Design and Prototyping Lab. Parts were bonded together
using adhesive transfer tapes (3M 468MP purchased from
Uline, Pleasant Prairie, WI, USA).
Device assembly
The three layers were held together using a set of custom-
made clamps. The final stack was assembled in this order:
layers P1, P2, P3, a flexible pad, and a bottom clamp. A layer
of lubricant (High vacuum grease, Dow Corning) was used
between layers P1, P2, and P3. We did not observe any effects
from the presence of this lubricant layer on the biological
assays described in this work (such as RNA purification andThis journal is © The Royal Society of Chemistry 2013
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View Article OnlineRT-qPCR). The flexible pad consisted of PDMS (silicone rub-
ber with adhesive back, 1.5 mm thick, McMaster Carr). The
same PDMS pad was cut using round punch tools to produce
the o-rings that create a tight seal during loading. For more
information, please refer to Fig. S1 (ESI†).
Device operation
P2 is the moving part of the device: by slipping P2 relative to
P1 and P3, the device can be placed in three different posi-
tions, each with a specific function. P2 begins in position 1
(“Loading”), in which the sample can be injected into the
device. One slip brings P2 to position 2 (“Drying”), in which
the sample is split into aliquots, disconnected from the inlet,
and exposed to the desiccant that has been pre-loaded into
the bottom portion (P3). The slip direction and distance are
guided by the clamping system. The user pushes P2 until it is
completely embedded in the device, which prevents acciden-
tal over-slipping. A second slip brings P2 to position 3
(“Recovery”), in which drying stops and the sample aliquots
are connected to through-holes for rehydration and
re-collection. This second slip can be performed only with a
special “slipping tool,” which was custom-made, in order to
avoid accidental slipping during storage and/or transport, or
by untrained users. After sample re-collection, the device can
be slipped back to position 2 for further storage.
Loading experiments
Loading was evaluated by placing a solution at the inlet hole
and placing the lid on the device, which created a tight seal.
This step generated extra pressure that pushed the sample
into the device. The solution was injected into the microwells
and channels only due to pressure, and not due to capillary
action through the polypropylene membrane: since the mem-
brane’s pores are hydrophobic and small (0.45 μm), only air
passes through at the pressures used for loading, allowing
the membrane to serve as a barrier between the sample and
drying agent. Of course, one may use wicking to fill the chan-
nels as well, but this was not the approach we took here. The
lid was designed to remain on the device during drying, stor-
age, and transport. The device can also be loaded by using a
standard pipettor, but we emphasize that a pipettor is not
required. Solutions that were successfully loaded into the
device included: DI water; DI water with 0.4 mM of BSA
(Sigma Aldrich); solutions of glycerol (Alfa Aesar) in water up
to 85% w/w; SsoFast™ EvaGreen® Supermix (Bio-Rad);
pooled normal human plasma (George King Biomedical,
Inc.); and human whole blood in Acid Citrate Dextrose (ACD)
(Zen-Bio Inc.). A green food dye was added to the solutions in
some experiments to enhance the contrast in photographs.
Videos and pictures of filling experiments were taken with a
camcorder (Sony Handycam HDR-CX190). For experiments
that estimated volume, images were analyzed using ImageJ
Software to approximate the fraction of each well containing
the solution. In addition, we implemented a “venting well”
strategy in the device through which extra air can evacuate inThis journal is © The Royal Society of Chemistry 2013the event of partial filling (see Fig. S4 in the ESI† for full
schematic drawings and mechanism description).Drying experiments
Devices were loaded as described above. After loading, the
central portion (P2) was moved to the drying position. In
some cases, the device was loaded using a pipettor instead of
the lid/o-ring system to allow a better view of the drying
dynamics in the channels. We tested both loading strategies
and they showed comparable results. For drying experiments,
P3 was pre-loaded using a desiccant, typically molecular
sieves, 4A, 1–2 mm beads (Alfa Aesar). Other desiccants were
successfully tested (CaCl2, CaSO4, and molecular sieves with
smaller diameter).
Slipping activates drying by putting the sample in
vapor contact with the molecular sieves. A polycarbonate
porous membrane embedded in P2 prevents contact
between sample and desiccant at this stage. Drying is
selectively activated: P2 and P3 both have a series of chan-
nels that do not overlap in the “Loading” and “Recovery”
positions. Only the “Drying” position aligns these chan-
nels, thus creating the vapor contact that drives the dry-
ing. Drying dynamics and timescale were characterized by
taking videos or photographs of the channels using a
camcorder or a camera.Recovery experiments
Samples were loaded and dried in the device using the tech-
niques described above. Both the pipettor and lid strategies
were used to load the devices used for the recovery experi-
ments. When a lid was used for the loading, it was removed
just before starting the recovery procedure. This ensured that
the recovery holes were enclosed during all handling and
storage to avoid possible contamination. We designed the
device so that slipping to the recovery position aligns the
wells with the recovery holes on P1. Each well can be inde-
pendently controlled, so the recovery can be total (all wells)
or partial (only one or more wells). In the experiments below,
rehydration was performed by injecting elution buffer (Buffer
AVE, Qiagen) into the wells containing dry sample and wait-
ing for it to dissolve. This process can be accelerated by
pipetting the solution back and forth in the wells using a
pipettor. Sample re-collection was performed by aspiration
with a standard pipettor. Washes can be performed by simply
re-injecting elution buffer into the wells and repeating the re-
collection procedure.
The recovered solution can be handled using the pipettor
and analyzed with conventional techniques. We tested the
recovery efficiency using water containing green food dye,
Phosphate buffered saline (PBS) with Alexa Fluor 488 (Sigma
Aldrich), or CdTe/Cds core/shell Quantum Dots (QD). QDs
were synthesized following a published method,22 with core
size between 2.5 and 3 nm and stock concentration on the
order of 2.6 μM.Lab Chip, 2013, 13, 4331–4342 | 4333
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View Article OnlinePlasma experiments
Human whole blood in Acid Citrate Dextrose (ACD) (Zen-Bio
Inc.) was spiked with inactivated HIV-1 viral particles
(AcroMetrix® HIV-1 Panel copies per mL, Life Technologies).
For each experiment, a 200 μL drop of blood was placed on
the plasma filtration membrane, and the lid was placed on
the device. The pressure generated by the lid was enough to
filter the plasma and to load the separated plasma into the
device wells. To help visualization of the separated plasma,
in some experiments green food dye or Alexa Fluor 488
(20 mM final concentration) were added to the starting blood
sample. After complete loading, the plasma was either re-
collected directly (to evaluate the filtration process) or treated
using the same process as was used for the other samples
(dried down, rehydrated, and re-collected). After re-collection,
HIV-1 RNA was purified from the plasma samples using
QIAamp MinElute Virus Spin Kit (Qiagen).
PCR amplification
RNA concentration was measured using reverse transcriptase
quantitative polymerase chain reaction (RT-qPCR). Primer
sequences for HIV-1 viral RNA were selected from a previous
publication: GRA ACC CAC TGC TTA ASS CTC AA; GAG GGA
TCT CTA GNY ACC AGA GT.23 To amplify HIV-1 viral RNA,
each 100 μL of RT-PCR mix contained the following: 50 μL of
2× EvaGreen SuperMix, 1 μL of each primer (10 μmol L−1),
2.5 μL of SuperScript® III Reverse Transcriptase, 37.5 μL of
RNA template solution, and 0.5 μL of nuclease-free water.
The amplifications were performed using an Eco Real-Time
PCR System (Illumina). To amplify the RNA, an initial 15 min
at 50 °C was applied for reverse transcription, then 2 min at
95 °C for enzyme activation, followed by 40 cycles of 30 s at
95 °C, 30 s at 55 °C, and 45 s at 72 °C. Melting curves were
acquired after the final cycle by bringing the samples to 95 °C
for 15 s, then to 53 °C for 15 s, and finally, back to 95 °C.
RNA storage experiments
Two different classes of purified RNA samples were used for
storage tests: Control RNA 250 (Ambion) and HIV-1 RNA puri-
fied from the AcroMetrix® HIV-1 Panel copies per mL (Life
Technologies). Purification was performed using the QIAamp
MinElute Virus Spin Kit (Qiagen).
Samples were diluted to the desired concentration (80 ng μL−1
for control RNA, 375 copies per microliter for HIV-1 RNA)
and mixed with a chemical stabilization matrix for RNA
(RNAStable, purchased from Biomatrica, Inc.).
Several aliquots of these solutions were injected into the
device and dried for stabilization. The devices were then
stored at 50 °C for up to 5 weeks. In parallel, several aliquots
of the same solution were used as controls. Controls included
aliquots stored in a −80 °C freezer and aliquots stored in the
liquid state at 50 °C in microcentrifuge tubes. Each storage
condition was performed in triplicate. At each time point, the
sample was recovered from the devices using the rehydration
and re-collection procedures, and three washes were4334 | Lab Chip, 2013, 13, 4331–4342performed for each well. All solutions were then diluted so
that the total volume of each aliquot was 100 μL.
Evaluation of RNA stability
Stability of the control RNA samples was tested by electropho-
resis using a 2100 Bioanalyzer (Agilent Technologies, Inc.)
with the RNA 6000 Nano Kit. Stability of the HIV-1 RNA sam-
ples was tested using RT-qPCR as described above.
Results and discussion
The general approach we pursued in this work was to bridge
limited-resource settings and laboratories by creating a device
that preserves samples that have been collected by untrained
users and allows reliable recovery of these samples in a cen-
tral facility. To satisfy the need for devices to be operated by
untrained users, we developed a device with three simple
steps (Fig. 1A–C) for handling and storage of samples: first,
the user places the collected sample at the device inlet; sec-
ond, the user places the lid on the device, which initiates
automated loading of the sample; and third, the user slips
the device, which splits the sample into aliquots and acti-
vates drying (Fig. 1D). At this stage, the device is ready for
shipment or storage, and no further manipulation of the
device by the untrained user is required.
The sample, which stays fully enclosed in the device,
remains stable and in the dry state during transport and/or
storage (Fig. 1E). At the desired time, a trained user can per-
form a second slip of the device with a special “slipping tool”
and rehydrate one or more of the aliquots by injecting water
into the wells (Fig. 1F) as detailed below. These rehydrated
aliquots can then be re-collected using a standard pipettor
and are ready for further analysis or purification (Fig. 1G). If
not all aliquots are needed for analysis, aliquots that are not
rehydrated can be stored long-term (e.g., for archival pur-
poses). Although the devices described in this paper are
prototypes, they were designed in consultation with manu-
facturers to ensure compatibility with mass production.
Device loading
In order to ensure simple and robust loading of the sam-
ple, we implemented two main design features that
enable several capabilities. The first design feature is a
“pumping lid,” which is a combination of an o-ring and
lid that limits the maximum pressure applied during
loading (Fig. 2A). The pumping mechanism used for sam-
ple loading is based on the use of a top lid that contains
a cavity. When the lid is placed on the device, a tight
seal is created with the flexible o-ring. This action com-
presses the air in the cavity and produces extra pressure,
which serves as the driving force for loading the sample
into the device. The maximum applied pressure is depen-
dent only on the lid geometry, and can be described as:
ΔPMAX = VO-RING/VCAVITY. This feature prevents the user
from accidentally applying excessive pressure, and mayThis journal is © The Royal Society of Chemistry 2013
Fig. 1 An overview of the operations and capabilities of the device. (A) A photograph representing the first step, in which an untrained user places the collected sample
(here, a green aqueous solution) at the device inlet. (B) A photograph of the device after the lid has been placed (left), which activates the automated filling process that
enables precise volume quantification (right). Sample preparation, such as plasma filtration, is integrated in this step. (C) A zoomed-in photograph of the device after the user
has performed the third step: a slip that disconnects the aliquots and activates drying. (D) A photograph showing the device after complete drying. (E) A photograph of an
agarose gel (inverted intensity) showing clear bands and no degradation, indicating that samples stored in the device remain stable without the need for refrigeration. (F) A
photograph of the device with one rehydrated well (green). Aliquots can be re-collected independently, so part of the sample may be kept dried for further storage. (G) A
graph showing a standard qPCR profile; recovered samples can be analyzed using traditional methods and instruments. Scale bars are 5 mm in all photographs. The loading
process is also shown in Video S1, ESI.†
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View Article Onlinebe useful for a wide range of microfluidic devices. In the
experiments described in this paper, we tested variousFig. 2 Automated loading with precise volume quantification. (A) A photograph (top) a
placed at the inlet, with a flexible o-ring surrounding the inlet. Lines have been added to
the device’s three major parts, or subassemblies), and solid, light gray lines outline wells
described in more detail in the ESI† (Fig. S5). (B) Photograph and schematic demonstratin
pressure and initiating loading. Wells are loaded sequentially (following the path indicated
well. (C1) A photograph of a fully loaded device, in which the sample volume (55 μL in th
has stopped automatically. (C2) A photograph of a partially loaded device, in which the
stops automatically as soon as air enters the first well (“venting well”), allowing quantitati
This journal is © The Royal Society of Chemistry 2013lid geometries, and the applied pressures ranged between
20 and 76 mbar.nd a schematic drawing (bottom) of an empty device, with a sample (green solution)
the photograph to illustrate the geometry (dashed lines outline ducts in P1 (one of
in P2). A light gray circle was used to indicate the via hole used for dead-end filling,
g that as the lid is placed on the device, it forms a tight seal with the o-ring, creating
by arrows) so that each well is completely filled before the solution enters the next
is case) is larger than the total device capacity (50 μL). All wells are filled, and loading
sample volume (25 μL in this case) is lower than the total device capacity. Loading
ve measurements to be obtained by counting full wells.
Lab Chip, 2013, 13, 4331–4342 | 4335
Fig. 3 A plot comparing injected volume as measured by the device with the
original sample volume. The relation is linear below 50 μL, which is the maximum
device capacity.
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View Article OnlineThe second design feature crucial for loading involves a
combination of dead-end and sequential filling that together
allow precise volume quantification. Dead-end filling is a
strategy previously applied for the loading of SlipChip
devices,24 in which the fluid (e.g., oil or air) originally present
in the wells or channels of the device is evacuated through
the gap between the device layers as the sample is entering
the wells or channels. In the cases previously reported, the
“sealing pressure” (defined as the maximum pressure that
can be used for loading the device without the sample enter-
ing the gap) is inversely proportional to the gap between the
device layers (see model described in ref. 24).
In the experiments described in this work, the air origi-
nally present in the wells of the device was pushed through
the membrane pores and evacuated through a via hole placed
in the proximity of the last well. A schematic description of
this mechanism is provided in the ESI† (Fig. S5). We empha-
size that the liquid sample is injected into the device wells
and channels only, and does not penetrate the porous mem-
brane that serves as the bottom of the device’s wells. This
configuration increases the range of loading pressures, as the
sealing pressure24 in this case is controlled by the size of the
pores in the membrane. As an example, when loading blood
plasma (surface tension 50 mN m−1) into a well filled with air
and using a membrane with a pore size of 0.45 μm, the seal-
ing pressure for the membrane is ~2 bar (roughly 4 times
more than the sealing pressure for a 1 μm gap between
plates). This value is significantly higher than the pressures
generated by the pumping lid, and we did not observe any
permeation of liquid through the porous membrane. Choos-
ing a membrane with an even smaller pore size would further
increase the sealing pressure, making the device resistant to
even higher loading pressures.
Filling stops automatically when all the wells are filled
with the sample, and any extra volume placed on the device
inlet is not injected into the device, providing an effective
control on the maximum loaded volume. With sequential fill-
ing (Fig. 2B), each well fills completely before the liquid
reaches the following well. If the input volume is lower than
the device capacity, loading stops automatically as soon as
the entire sample has been injected (Fig. 2C). Any extra air
that follows the end of the liquid sample slug can be vented
through an extra “venting well” in the storage layer to stop
filling. The original volume of sample can then be quantified
by counting the number of full wells or by taking a picture of
the device after filling and analyzing it using ImageJ Software
to approximate the fraction of each well containing the solu-
tion. Repeated loading experiments demonstrated that filling
is consistent with these predictions (Fig. 3).
These design features obviate the need for users to pre-
cisely control pressure and input volume, both of which are
challenging operations without proper training and equip-
ment. Knowledge of the input volume is critical for calculat-
ing concentrations of analytes in the biofluid being preserved
and then analyzed. Moreover, we demonstrated that a wide
range of solutions can be loaded using this approach (see4336 | Lab Chip, 2013, 13, 4331–4342Table S1 and Video S1 in the ESI†). The large flexibility in
pressures, ensured by the modified dead-end filling mecha-
nism described above, made it possible to rapidly drive fluids
with the viscosity of water (with velocities up to 10 μL s−1)
through the device. This loading approach was also suitable
for loading samples with a wide range of properties, including
viscosities up to 110 mPa s (85% w/w of glycerol in water) and
surface tensions down to 7 mN m−1 (0.4 mM BSA). For this
BSA solution, the calculated sealing pressure was 0.31 bar.
In this work, the matrix was pre-mixed with the sample
prior to injection into the device. The device has been
designed to be compatible with a variety of matrices, even
those not yet developed. The preferred method of incorporat-
ing a specific preservation matrix into the device would
depend on the properties of the particular matrix and its dis-
solution kinetics.Aliquoting and drying
Once loading is complete, aliquoting and rapid drying are ini-
tiated by a single slip that is controlled by an internal mecha-
nism to prevent over-slipping. We designed the device so that
slipping to the drying position (i) disconnects the wells from
the inlet and isolates all the wells from one another, and (ii)
activates drying by exposing the sample in the wells to the
pre-loaded desiccant in P3, one of the device’s three major
parts or subassemblies (see Experimental). This slip also
embeds the central layer (P2) in the device so that it cannot
be inadvertently un-slipped during shipment or storage. The
slipping step is shown in Video S1, ESI.†
After the user has performed the slip, the drying process
in each well begins with the nucleation of an air bubble that
grows as evaporation occurs (Fig. 4). We relied on a well-
understood idea25–28 that by reducing length scales over
which evaporation takes place, vapor transfer can be acceler-
ated. This process is rapid also because evaporation takes
place through the porous membrane that serves as the bot-
tom layer of the wells. The surface to volume ratio in this
case was 3.3 mm2 for each μL. Drying times for the differentThis journal is © The Royal Society of Chemistry 2013
Fig. 4 An overview of slip-initiated drying. (A) A photograph (top) and schematic drawing (bottom) showing the device after loading. In this case, the device was loaded
with a pipettor instead of using the “pumping lid” to ensure unobstructed visualization of the sample wells. (B) A photograph and a schematic drawing of the device once it
has been slipped. The slip disconnects wells and allows vapor contact between the sample and the desiccant (black). Evaporation starts by nucleation of an air bubble in each
well. (C) A photograph and a schematic drawing showing drying in progress. The bubbles grow due to progressive loss of water caused by evaporation. (D) A photograph and
a schematic drawing of the device once drying is complete and the sample is stabilized (green sample residuals are visible in the wells). (E) A plot showing the fraction of the
wells containing liquid over time for a representative device. See ESI† (Fig. S6) for full schematic drawings and operation of the device.
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View Article Onlinesolutions tested were typically on the order of 30–45 min for
a total volume of 50 μL (Fig. 4E) (see Fig. S6 and Video S2 in
the ESI† for drying dynamics). As a comparison, the same
volume in a microcentrifuge tube required up to 12 hours to
be evaporated in a laboratory environment. These timescales
were suitable for the storage experiments shown in this
paper, but this framework offers a wide range of drying times
that can be adjusted by changing device parameters such as
the volume of wells, surface-to-volume ratio, type of desic-
cant, and membrane properties (such as pore size, fractional
open area of the membrane, and membrane thickness). After
drying is complete, the presence of sample in each well can
be confirmed by the presence of solid residuals (Fig. 4C and
D), which can be used as a strategy to detect empty wells in
the event of partial filling.Recovery
A second slip allows a trained user to selectively recover
stored aliquots through the device’s sterile pathways. As
mentioned above, the device is designed so that the central
layer is completely embedded in the device during storage
or transport to prevent accidental slipping during transit or
by untrained users. A special slipping tool (Fig. 5A and B) is
required to perform this second slip. When the device is inThis journal is © The Royal Society of Chemistry 2013the recovery position, vapor contact with the drying agent in
P3 is blocked; in our experiments, no evaporation was
observed. In addition, each well is connected with two
through-holes that have not been used during loading and
are thus free from contaminants. These holes were designed
to match the size of pipettor tips, ensuring robustness of
the recovery step. A pipettor can be used to inject water into
the wells to dissolve the dry sample (Fig. 5C). Rehydration
times for standard solutions ranged from 1 to 20 min,
depending on the solubility of the solid residual and on the
channel geometry. These timescales can be further reduced
by using the pipettor to perform back-and-forth injection of
the solution, thus speeding up the dissolution (see Video S3
in the ESI†).
After rehydration, the sample can be retrieved from each
well by aspirating with a standard pipettor (Fig. 5D). Using
this procedure, we re-collected liquid solutions with the same
concentration as the injected sample, demonstrating that
quantitative measurements can be obtained from stored ali-
quots (Fig. 5E and F). We evaluated the reliability of recovery
by injecting solutions containing either fluorescent molecules
(Alexa Fluor 488) or nanoparticles (CdTe/Cds quantum dots)
(Fig. 5E and F). After drying and rehydration, the solutions
were re-collected from the wells of the device. This method
allowed quantitative measurements: solutions with differentLab Chip, 2013, 13, 4331–4342 | 4337
Fig. 5 An overview of sample rehydration and recovery. (A) A photograph (top) and a schematic drawing (bottom) of the device containing dry sample after 12 hours,
along with a drawing of a separate “slipping tool” used for slipping to the recovery position. (B) A photograph and a schematic drawing showing a device that has been
slipped to the recovery position using the special slipping tool. (C) A photograph and a schematic drawing of the device after selective rehydration of a single well with a
pipettor. (D) A photograph and a schematic drawing showing selective recovery of the sample from a single rehydrated well (other aliquots remain dry for further storage).
Full schematics and operation of the device in A–D are available in the ESI† (Fig. S7). (E) A graph showing quantitative recovery of quantum dot solutions after drying has
taken place in the device. (F) A graph showing quantitative recovery of Alexa Fluor 488 solutions after drying has taken place in the device, compared to the original
solution (“control”). In E and F, brackets indicate p values, the null hypothesis being that the two concentrations were the same in each case. Error bars represent the 95%
confidence interval (n = 3 for each condition). See Fig. S8 and S9† for calibration curves, Tables S2 and S3† for statistical calculations, and Video S3† for demonstration of
rehydration and recovery in the ESI.†
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View Article Onlineconcentrations were reliably distinguished, showing clear dif-
ference between solutions with a 2-fold difference in dilution
(all p values were 5 × 10−5 or less, the null hypothesis being
that the two concentrations were the same in each case). No
more than ±10% difference was observed when comparing
the signal from the rehydrated aliquots with the starting stock
solution (see Tables S2 and S3 in the ESI†). If needed, liquid
residuals in the channel can be washed out by injecting more
water into the well and re-collecting the solution; the washing
step can be repeated additional times if necessary.
Since each well is individually retrievable, a trained user
can rehydrate one or more wells and perform either partial or
total recovery of the original sample. If only a portion of the
total number of wells is recovered, the device can be slipped
back to the drying position for further storage.Integration with plasma processing
We have next shown that this device can be integrated with a
plasma separation module without changes to the device’s
architecture or operation. We introduced a porous membrane
(Vivid Plasma Separation Membrane, Grade GR) into the P1
subassembly to filter whole blood and obtain cell-free plasma4338 | Lab Chip, 2013, 13, 4331–4342(Fig. 6A). After filtration, separated plasma flowed directly
into the device wells (in practice, this eliminates the need for
involvement from untrained users). The same “pumping lid”
approach described earlier (Fig. 2) was used here both for
plasma separation and device loading. The device is designed
to process as much as 200 μL of whole blood, a volume that
can reasonably be collected by finger pricks. This input vol-
ume was suitable for complete loading of all the devices that
were tested (Fig. 6B). To aid visibility of plasma, dye can be
added to whole blood, as was done in Fig. 6B with Alexa Fluor
488, and in Fig. S10 in the ESI,† in which we used a green food
dye. In the future, the membrane itself may be treated with a
visible dye. In addition, visualization and thus quantification
may also be enabled by the use of commercially available
“indicating drying agents” that change color in the presence
of humidity. In this approach, only the drying agent in close
contact with the wells containing sample would change color,
allowing one to count the number of filled wells. While we
did not use such a drying agent in this work, we expect this
approach should be compatible with this device. Additionally,
the plasma filtration membrane may eventually be treated
directly with a preservation matrix so that the matrix will
automatically release during the filtration step.This journal is © The Royal Society of Chemistry 2013
Fig. 6 Integration of the sample preservation device with a plasma filtration module. (A) Schematic drawings that show the components of the plasma filtration module
(top) and the process for obtaining cell-free plasma with this module (bottom). The pumping lid is used both to obtain plasma and to load the device. (B) Two photographs of
the device after the lid has been closed and plasma has been successfully obtained from whole blood and loaded into the wells. Whole blood was spiked with 20 mM of
Alexa Fluor 488 to aid visualization of the separated plasma. Left: Bright-field image, showing the red and white blood cells (residuals) at the device inlet and the plasma
loaded in the wells. Right: Fluorescence image of the device (for improved visualization of the plasma within the wells). (C) A graph comparing quantification results of HIV-1
RNA from plasma extraction with a traditional centrifuge (left) and extraction using the device’s plasma filtration module (right). p Values are in the same range for both tech-
niques: *** indicates a p value of less than 0.001, and n.s. indicates a p value higher than 0.05 (no significant difference) (see Table S4 in the ESI† for full details of statistical
analysis). The null hypothesis for p values was that both concentrations were equivalent. Error bars represent the 95% confidence interval (n = 3 for all experiments, except
for the centrifugation experiment at the lower concentration, for which n = 5).
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View Article OnlineUsing this filtration approach, we successfully separated
plasma from whole blood that was spiked with HIV-1 viral
particles. We were able to purify HIV-1 RNA from these
plasma samples. Compared to plasma controls separated by
centrifugation, the recovery rate of HIV-1 RNA after plasma
filtration with this device was always more than 60%. We
used different concentrations of HIV-1 particles and found
that the p values were comparable for the control samples
and the device (1.2 × 10−4 for the centrifuge and 1.6 × 10−4
for the device) (Fig. 6C) (see Table S4 in the ESI† for p
value calculations).
Since there is currently no chemical matrix available
for stabilization of HIV-1 RNA in plasma, we did not test
the stability of preserved RNA in plasma. However, we ver-
ified that the device can successfully dry normal plasma.
We demonstrated that injected plasma can be dried down,
stored, and re-collected as described earlier (see Fig. S10
in the ESI† for details). Rehydration times for plasma
were longer (on the order of 15–20 min) than for the pre-
vious experiments, so we typically injected the water back
and forth with a pipettor to speed up the dissolution. One
critical parameter is the speed at which the plasma sam-
ples are dried. Since, in the dry state, blood plasma pro-
duces more solid residuals than purified solutions, there
is a risk that the wells may get clogged when the sample
dries. The device’s fast drying times avoided this problem
by distributing residuals across the walls of the wells,
allowing successful rehydration of all wells (Fig. S10 in
the ESI†). In contrast, when we tested the drying of
plasma through the porous membrane using the P2 sub-
assembly alone (not integrated with the device) and no
desiccant to drive the drying process, times for drying
were on the order of 1 to 2 hours, and the solid residualsThis journal is © The Royal Society of Chemistry 2013tended to accumulate in one spot in the wells and block
the fluidic path for rehydration.Sample stabilization
We validated the preservation and recovery capabilities of the
device and its compatibility with commercially available
matrices by using control RNA and HIV-1 RNA. We chose
RNA because it is less stable than DNA29 and because it is rel-
evant for quantifying HIV-1 viral load. Recent work30 has
shown that purified RNA stored dry in a solid-phase extrac-
tion cartridge (without stabilization matrices) remained sta-
ble for about one week at 37 °C, and degradation was
observed for longer storage times. In the following experi-
ments, we introduced RNA buffer into the device using the
pumping lid mechanism, slipped to initiate drying, and
placed the device in an incubator at the test temperature.
To test general RNA stability, we used a mixture of control
RNA 250 (Ambion) and a stabilization matrix (RNAStable,
Biomatrica). Electrophoresis experiments performed with an
Agilent 2100 Bioanalyzer showed that the 80 ng μL−1 of con-
trol RNA aliquots stored dry in the device for 4 days at 50 °C
did not show any detectable degradation, indistinguishable
from the controls stored in a freezer at −80 °C (see Table S5
and Fig. S11 in the ESI† for full details, evaluated semi-
quantitatively using an approach similar to the one described
previously).31,32 As a comparison, degradation of control RNA
was obvious in aliquots stored in the liquid state at 50 °C,
evidenced by the presence of short products that formed a
smear pattern (Fig. 7A).
Next, we showed that the device also allowed stabilization
and quantitative recovery of HIV-1 RNA. RNA was purified
from inactivated HIV-1 viral particles (see Experimental).Lab Chip, 2013, 13, 4331–4342 | 4339
Fig. 7 Validation of the device using control RNA and HIV-1 RNA. (A) Densitometry plot showing electrophoresis results from control RNA (80 ng μL
−1
) mixed with a stabili-
zation matrix (RNAStable, Biomatrica) and stored for four days under different conditions. (B) A graph showing the results of quantitative analysis of purified HIV-1 samples
performed with RT-qPCR. Error bars represent the 95% confidence interval (n = 3). Stars are used to indicate p values: * if the p value is less than 0.05, ** if less than 0.01,
and *** if less than 0.001. See Table S7 in the ESI† for calculations.
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View Article OnlineAliquots (10 μL) containing ~3750 copies of RNA and mixed
with the preservation matrix were stored in one of three con-
ditions: (i) frozen at −80 °C, (ii) in the device in the dry state
at 50 °C, or (iii) in the liquid state at 50 °C in microcentrifuge
tubes. Experiments at elevated temperatures are typically
used to evaluate long-term stability of samples in a reason-
able amount of experimental time; furthermore, such experi-
ments reflect temperature fluctuations to which samples may
be exposed during shipping when temperature is not con-
trolled. Since this RNA was at a low concentration (375 copies
μL−1), RT-qPCR was used to evaluate stability and recovery
rate. Quantification cycles (Cq) were measured for each stor-
ing condition and were compared with controls (aliquots
stored at −80 °C) (Fig. S12 and S13 and Table S6†). Liquid
samples stored at 50 °C showed significant degradation after
as few as 7 days (p value = 0.04), and this degradation
became more prominent over time (p value after 35 days was
6.1 × 10−8) (see Fig. 7B and Table S7 in the ESI†). When com-
paring the frozen controls and those samples stored in the
device at 50 °C, we observed a minor difference in Cq values
(0.5 cycles on average, n = 18), but no substantial change
(always less than 0.3 cycles) in Cq was observed over a 5-week
period. Stability of the RNA at 50 °C over a 5-week period in
this “accelerated aging” test17,33 implies that the RNA may be
stable at room temperature in the device for as long as
8 months.17,33
Conclusions
We developed and validated a device for using chemical sta-
bilization matrices to preserve samples in the dry state. This
device is portable, compact, and self-contained, so it can be
transported and operated by minimally trained users even in
low-resource settings. An integrated plasma separation4340 | Lab Chip, 2013, 13, 4331–4342approach further increases the device’s relevance to resource-
limited settings. In addition, while so far we have tested pro-
totypes manufactured on the scale of 100 devices, the device
architecture, structure, and operation are compatible with
mass production to enable large-scale manufacturing. The
features of this device, including dead-end and sequential
filling, driven by the pumping lid, as well as the modularity
of this platform (which facilitates integration and simplifies
operation) would be applicable to other microfluidic devices
beyond this application. The described device allows for sub-
sequent recovery of preserved samples in a centralized labo-
ratory, enabling quantitative measurements and volume
quantification over a wide range (5–50 μL in the current ver-
sion, and scalable to up to 1 mL). We have demonstrated that
this device is compatible with standard laboratory tech-
niques, and we anticipate that it will be made compatible
with SlipChip-based microfluidic strategies for biological
analysis to enable rapid point-of-use sample processing and
analysis with preservation of the excess sample.34–36
Now that we have demonstrated and validated the fea-
tures of the device such as pumping, modular design, inte-
gration of plasma filtration, and aliquoting, the next step is
to develop and test new matrices to stabilize desired tar-
gets, such as HIV-1 RNA in plasma. We emphasize that in
this work, we did not create new chemical stabilization
matrices and used only those commercially available. The
range of applications of this device will expand as addi-
tional matrices are being developed in this active field of
research. We envision that the device will be used for
remote analysis, allowing quantitative tests such as quanti-
fying viral load or genotyping for viral infection (of HIV,
HCV, etc.). While we focused on preservation and recovery
of nucleic acids, we have demonstrated that this approach
is also compatible with recovery of small molecules andThis journal is © The Royal Society of Chemistry 2013
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View Article Onlineparticles. Recovery of small molecules is attractive for
studying pharmacokinetics in clinical trials of drug candi-
dates.10,11 Preservation of proteins and live organisms
using this approach is of active interest to us as well.
Examples of other potential applications include the test-
ing of different analytes from a single sample (multiplexing)
by using more than one stabilization matrix, as well as
multi-patient testing achieved by the storage of more than
one sample in the same device. In addition, sample stabiliza-
tion during transport could also facilitate large-scale, remote
clinical trials by allowing subjects to collect samples at home
in order to minimize the costs of traveling to a centralized
facility, sample collection, and analysis. Another potential
application of analyte stabilization is the ability to track the
clinical history of a patient by preserving samples collected
regularly over a long period of time. This would dramatically
increase the amount of available information for personal-
ized medicine, allowing one to trace the temporal evolution
of disease and biomarkers not only after the diagnosis, but
potentially over a patient’s lifetime. This approach is cur-
rently unfeasible due to the high costs of cold-chain stabili-
zation and biobanking, but it would be enabled by further
developments of bio-preservation reagents and of integrated,
simple-to-use microfluidic devices of the type described here.Acknowledgements
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